277 related articles for article (PubMed ID: 33504942)
1. Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target.
Palacios F; Yan XJ; Ferrer G; Chen SS; Vergani S; Yang X; Gardner J; Barrientos JC; Rock P; Burack R; Kolitz JE; Allen SL; Kharas MG; Abdel-Wahab O; Rai KR; Chiorazzi N
Leukemia; 2021 Apr; 35(4):1037-1052. PubMed ID: 33504942
[TBL] [Abstract][Full Text] [Related]
2. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
Chiang CL; Goswami S; Frissora FW; Xie Z; Yan PS; Bundschuh R; Walker LA; Huang X; Mani R; Mo XM; Baskar S; Rader C; Phelps MA; Marcucci G; Byrd JC; Lee LJ; Muthusamy N
Blood; 2019 Aug; 134(5):432-444. PubMed ID: 31151986
[TBL] [Abstract][Full Text] [Related]
3. High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle.
Caraballo JM; Acosta JC; Cortés MA; Albajar M; Gómez-Casares MT; Batlle-López A; Cuadrado MA; Onaindia A; Bretones G; Llorca J; Piris MA; Colomer D; León J
Oncotarget; 2014 Jul; 5(13):4694-708. PubMed ID: 25051361
[TBL] [Abstract][Full Text] [Related]
4. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
Tonino SH; Mulkens CE; van Laar J; Derks IA; Suo G; Croon-de Boer F; van Oers MH; Eldering E; Wang JY; Kater AP
Leuk Lymphoma; 2015; 56(8):2439-47. PubMed ID: 25511680
[TBL] [Abstract][Full Text] [Related]
5. Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin.
Han Y; Ye A; Zhang Y; Cai Z; Wang W; Sun L; Jiang S; Wu J; Yu K; Zhang S
PLoS One; 2015; 10(8):e0136484. PubMed ID: 26308531
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-143 acts as a tumor suppressor through Musashi-2/DLL1/Notch1 and Musashi-2/Snail1/MMPs axes in acute myeloid leukemia.
Li F; Han Y; Chen R; Jiang Y; Chen C; Wang X; Zhou J; Xu Q; Jiang S; Zhang S; Yu K; Zhang S
J Transl Med; 2023 May; 21(1):309. PubMed ID: 37149661
[TBL] [Abstract][Full Text] [Related]
7. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
8. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.
Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Lowdell MW; Samuel ER; North JM; Nacheva EP; Chanalaris A; Kottaridis P; Cwynarski K; Wickremasinghe RG
Blood; 2009 Aug; 114(6):1217-25. PubMed ID: 19515722
[TBL] [Abstract][Full Text] [Related]
9. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Byrd JC; Shinn C; Waselenko JK; Fuchs EJ; Lehman TA; Nguyen PL; Flinn IW; Diehl LF; Sausville E; Grever MR
Blood; 1998 Nov; 92(10):3804-16. PubMed ID: 9808574
[TBL] [Abstract][Full Text] [Related]
11. Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.
Pramil E; Herbi Bastian L; Denèfle T; Nemati F; Xiao M; Lardé E; Maloum K; Roos-Weil D; Chapiro E; Le Garff-Tavernier M; Davi F; Decaudin D; Sarfati M; Nguyen-Khac F; Merle-Béral H; Karoyan P; Susin SA
Blood Adv; 2019 Oct; 3(20):2920-2933. PubMed ID: 31648314
[TBL] [Abstract][Full Text] [Related]
12. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
13. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia.
Kharas MG; Lengner CJ; Al-Shahrour F; Bullinger L; Ball B; Zaidi S; Morgan K; Tam W; Paktinat M; Okabe R; Gozo M; Einhorn W; Lane SW; Scholl C; Fröhling S; Fleming M; Ebert BL; Gilliland DG; Jaenisch R; Daley GQ
Nat Med; 2010 Aug; 16(8):903-8. PubMed ID: 20616797
[TBL] [Abstract][Full Text] [Related]
14. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
15. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway.
Zhang H; Tan S; Wang J; Chen S; Quan J; Xian J; Zhang Ss; He J; Zhang L
Exp Cell Res; 2014 Jan; 320(1):119-27. PubMed ID: 24076374
[TBL] [Abstract][Full Text] [Related]
16. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
[TBL] [Abstract][Full Text] [Related]
17. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.
Papakonstantinou N; Ntoufa S; Chartomatsidou E; Kotta K; Agathangelidis A; Giassafaki L; Karamanli T; Bele P; Moysiadis T; Baliakas P; Sutton LA; Stavroyianni N; Anagnostopoulos A; Makris AM; Ghia P; Rosenquist R; Stamatopoulos K
Oncotarget; 2016 Jun; 7(24):35946-35959. PubMed ID: 27191993
[TBL] [Abstract][Full Text] [Related]
18. Activation of
Biran A; Yin S; Kretzmer H; Ten Hacken E; Parvin S; Lucas F; Uduman M; Gutierrez C; Dangle N; Billington L; Regis FF; Rassenti LZ; Mohammad A; Hoffmann GB; Stevenson K; Zheng M; Witten E; Fernandes SM; Tausch E; Sun C; Stilgenbauer S; Brown JR; Kipps TJ; Aster JC; Gnirke A; Neuberg DS; Letai A; Wang L; Carrasco RD; Meissner A; Wu CJ
Cancer Res; 2021 Dec; 81(24):6117-6130. PubMed ID: 34686499
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.
Kasar S; Underbayev C; Yuan Y; Hanlon M; Aly S; Khan H; Chang V; Batish M; Gavrilova T; Badiane F; Degheidy H; Marti G; Raveche E
Oncogene; 2014 Jun; 33(25):3307-15. PubMed ID: 23995789
[TBL] [Abstract][Full Text] [Related]
20. Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia.
Abo Elwafa R; Abd Elrahman A; Ghallab O
Clin Transl Oncol; 2021 Jan; 23(1):92-99. PubMed ID: 32468342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
